Objective:To explore the efficacy difference of two different routes of intracoronary verapamil on no-reflow phe-nomenon during primary percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial in-farction (STEMI) .Methods :From January 2009 to December 2012 ,141 STEMI patients with no-reflow phenomenon during e-mergency PCI who received the manual intracoronary bolus infusion of verapamil were selected .According to the routes of in-tracoronary verapamil ,patients were divided into guiding catheter group (n=67) and selective catheter group (n=74) .The coronary perfusion level ,the ECG ST-segment resolution ,left ventricular ejection fraction (LVEF) and major adverse cardiac events in 30 days post-PCI were compared .Results:There were no statistically significant differences in general datum of the two groups and the average dose of intracoronary infusion verapamil (P>0 .05) .The level of cTFC in the the selective catheter group was significantly lower than that in the guiding catheter group (P<0 .05) .More patients restored the TIMI-3 flow after drug infusion in selective catheter group than guiding catheter group (P<0 .05) .The proportion of complete ST-segment reso-lution after PCI in the selective catheter group was significantly higher than that in guiding catheter group (P<0 .05) .No sta-tistically significant differences were found in LVEF and incidence of major adverse cardiac events during 30 days between the two groups (both P>0 .05) .Conclusions :The intracoronary verapamil through selective catheter can reverse no-reflow phe-nomenon more effectively than through guiding catheter during emegency PCI for STEMI .

The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
Adalimumab ; Asia ; Asian Continental Ancestry Group ; Biological Factors ; Biosimilar Pharmaceuticals ; Colitis ; Colitis, Ulcerative ; Consensus ; Cooperative Behavior ; Crohn Disease ; Gastroenterology ; Hepatitis B ; Humans ; Immunologic Factors ; Inflammatory Bowel Diseases ; Infliximab ; Pharmacogenetics ; Philippines ; Practice Guidelines as Topic ; Tuberculosis ; Ulcer